Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

461. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial

Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

462. A target backrest elevation of 45° was not feasible for mechanically ventilated patients; elevations achieved did not prevent ventilator associated pneumonia

A target backrest elevation of 45° was not feasible for mechanically ventilated patients; elevations achieved did not prevent ventilator associated pneumonia A target backrest elevation of 45° was not feasible for mechanically ventilated patients; elevations achieved did not prevent ventilator associated pneumonia | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) patients; elevations achieved did not prevent ventilator associated pneumonia Article Text Treatment A target backrest elevation of 45° was not feasible for mechanically ventilated patients; elevations achieved did not prevent ventilator associated pneumonia Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price

2006 Evidence-Based Nursing

463. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. Full Text available with Trip Pro

Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. Pneumonia causes significant mortality and morbidity among persons aged 65 years or older. However, few studies have explored trends according to age groups, which may affect intervention strategies.To examine trends in hospitalizations for pneumonia among persons aged 65 years or older and to compare characteristics, outcomes, and comorbid diagnoses.Data from 1988 through 2002 (...) on pneumonia and comorbid diagnoses among patients aged 65 to 74 years, 75 to 84 years, and 85 years or older from the National Hospital Discharge Survey.Hospitalization rates by first-listed and any-listed discharge codes for pneumonia; proportions of hospitalizations reporting comorbid diagnoses for the 3 age groups (65-74 years, 75-84 years, > or =85 years).Hospitalization rates by both first-listed and any-listed discharge codes for pneumonia increased by 20% from 1988-1990 to 2000-2002 for patients

2005 JAMA

464. Effect of weekly zinc supplements on incidence of pneumonia and diarrhoea in children younger than 2 years in an urban, low-income population in Bangladesh: randomised controlled trial. (Abstract)

Effect of weekly zinc supplements on incidence of pneumonia and diarrhoea in children younger than 2 years in an urban, low-income population in Bangladesh: randomised controlled trial. Pneumonia and diarrhoea cause much morbidity and mortality in children younger than 5 years. Most deaths occur during infancy and in developing countries. Daily regimens of zinc have been reported to prevent acute lower respiratory tract infection and diarrhoea, and to reduce child mortality. We aimed to examine (...) whether giving zinc weekly could prevent clinical pneumonia and diarrhoea in children younger than 2 years.1665 poor, urban children aged 60 days to 12 months were randomly assigned zinc (70 mg) or placebo orally once weekly for 12 months. Children were assessed every week by field research assistants. Our primary outcomes were the rate of pneumonia and diarrhoea. The rates of other respiratory tract infections were the secondary outcomes. Growth, final serum copper, and final haemoglobin were also

2005 Lancet Controlled trial quality: predicted high

465. Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Full Text available with Trip Pro

Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as an important cause of community-acquired lower respiratory tract infection (LRTI) in children. Pulmonary manifestations are typically tracheobronchitis or pneumonia but M. pneumoniae is also implicated in wheezing episodes in both asthmatic and non-asthmatic individuals. Although antibiotics are used to treat (...) LRTI, a review of several major textbooks offers conflicting advice for the use of antibiotics in the management of M. pneumoniae LRTI in children.To determine whether antibiotics are effective in the treatment of childhood LRTI secondary to M. pneumoniae infections acquired in the community.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2005), which contains the ARI Group's specialised register of trials; MEDLINE (1966 to February 2005

2005 Cochrane

466. Continuous subglottic suction is effective for prevention of ventilator associated pneumonia

Continuous subglottic suction is effective for prevention of ventilator associated pneumonia BestBets: Continuous subglottic suction is effective for prevention of ventilator associated pneumonia Continuous subglottic suction is effective for prevention of ventilator associated pneumonia Report By: Rahul Gujadhur, Bruce W. Helme, Aliu Sanni and Joel Dunning - Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Section Editor ICVTS Institution: Department of Cardiothoracic (...) Surgery, Freeman Hospital, Newcastle upon-Tyne Date Submitted: 3rd May 2005 Date Completed: 26th May 2005 Last Modified: 17th May 2005 Status: Green (complete) Three Part Question In patients undergoing [mechanical ventilation] does [subglottic suction] reduce the incidence of [Ventilator associated pneumonia]? Clinical Scenario You performed a difficult Aortic Valve replacement and triple-coronary arterial-bypass-graft on a 77-year-old man, with a 30-year history of smoking. The operation proceeded

2005 BestBETS

467. Symptoms and signs plus erythrocyte sedimentation rate or C-reactive protein predicted pneumonia in lower respiratory tract infection Full Text available with Trip Pro

Symptoms and signs plus erythrocyte sedimentation rate or C-reactive protein predicted pneumonia in lower respiratory tract infection Symptoms and signs plus erythrocyte sedimentation rate or C-reactive protein predicted pneumonia in lower respiratory tract infection | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Symptoms and signs plus erythrocyte sedimentation rate or C-reactive protein predicted pneumonia in lower respiratory

2005 Evidence-Based Medicine

468. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. (Abstract)

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Pneumonia is estimated to cause 2 million deaths every year in children. Streptococcus pneumoniae is the most important cause of severe pneumonia. We aimed to assess the efficacy of a nine-valent pneumococcal conjugate vaccine in children.We undertook a randomised, placebo-controlled, double-blind trial in eastern Gambia (...) . Children age 6-51 weeks were randomly allocated three doses of either pneumococcal conjugate vaccine (n=8718) or placebo (8719), with intervals of at least 25 days between doses. Our primary outcome was first episode of radiological pneumonia. Secondary endpoints were clinical or severe clinical pneumonia, invasive pneumococcal disease, and all-cause admissions. Analyses were per protocol and intention to treat.529 children assigned vaccine and 568 allocated placebo were not included in the per

2005 Lancet Controlled trial quality: predicted high

469. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. (Abstract)

Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Most studies of Haemophilus influenzae type b (Hib) disease in Asia have found low rates, and few Asian countries use Hib vaccine in routine immunisation programmes. Whether Hib disease truly is rare or whether many cases remain undetected is unclear.To estimate incidences of vaccine-preventable Hib pneumonia and meningitis among children (...) children: 28147 were assigned DTP-PRP-T and 26926 DTP. The proportion of pneumonia outcomes prevented by vaccine ranged from less than 0 to 4.8%. Calculated incidences of vaccine-preventable Hib disease (per 10(5) child-years of observation) for outcome categories were: substantial alveolar consolidation or effusion, less than zero (-43 [95% CI -185 to 98]); all severe pneumonia, 264 (95% CI less than zero to 629); all clinical pneumonia, 1561 (270 to 2853); confirmed Hib meningitis, 16 (1.4 to 31

2005 Lancet Controlled trial quality: predicted high

470. A clinical and economic study of community-acquired pneumonia between single versus combination therapy

A clinical and economic study of community-acquired pneumonia between single versus combination therapy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

471. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. Full Text available with Trip Pro

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. Chlamydia pneumoniae has been found within atherosclerotic plaques, and elevated titers of antibody to this organism have been linked to a higher risk of coronary events. Pilot studies have suggested that antibiotic treatment may reduce the risk of cardiovascular events.We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and evaluated the efficacy of long-term (...) treatment with gatifloxacin, a bactericidal antibiotic known to be effective against C. pneumoniae, in a double-blind, randomized, placebo-controlled trial. Subjects received 400 mg of gatifloxacin daily during an initial 2-week course of therapy that began 2 weeks after randomization, followed by a 10-day course every month for the duration of the trial (mean duration, 2 years), or placebo. The primary end point was a composite of death from all causes, myocardial infarction, documented unstable angina

2005 NEJM Controlled trial quality: predicted high

472. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis

Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis Shorr A F, Sherner J H, Jackson W L, Kollef M H CRD summary This review found that invasive strategies for the diagnosis of ventilator-associated pneumonia did not affect mortality, but did result in changes to the prescribing (...) of antibiotics. This was generally a well-conducted review and these conclusions are likely to be reliable. Authors' objectives To investigate whether invasive testing of patients with ventilator-associated pneumonia (VAP) affects antibiotic management and mortality. Searching MEDLINE (1966 to December 2003), EMBASE (1990 to December 2003) and the Cochrane Library were searched; key terms were reported. Abstracts from relevant conferences were handsearched, reference lists of retrieved studies screened

2005 DARE.

473. Efficacy of heat and moisture exchangers in preventing ventilator-associated pneumonia: meta-analysis of randomized controlled trials

Efficacy of heat and moisture exchangers in preventing ventilator-associated pneumonia: meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

474. Quinolones for treatment of nosocomial pneumonia: a meta-analysis

Quinolones for treatment of nosocomial pneumonia: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

475. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis

Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

476. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis

Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

477. Do guidelines guide pneumonia practice: a systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia

Do guidelines guide pneumonia practice: a systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

478. Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia

Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community (...) acquired pneumonia Yaqub A, Khan Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the early switch from intravenous to oral amoxicillin-clavulanate in the treatment of hospitalised patients with community-acquired

2005 NHS Economic Evaluation Database.

479. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care Full Text available with Trip Pro

An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care Skrepnek G H, Armstrong E P, Malone D C, Ramachandran S Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four first-line monotherapy options for the treatment of community-acquired pneumonia (CAP) were examined. The options were erythromycin (ERY), azithromycin (AZI), clarithromycin (CLA) and levofloxacin (LEV). Type of intervention

2005 NHS Economic Evaluation Database.

480. Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia

Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia Frei C R, Burgess D S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four empiric antimicrobial regimens used to treat adults with community-acquired pneumonia (CAP) were examined. The regimens were levofloxacin monotherapy (Levo), ceftriaxone monotherapy (CTX), ceftriaxone plus a macrolide (CTX+Mac), and ceftriaxone plus levofloxacin (CTX+Levo). Type of intervention Treatment. Economic study type Cost-effectiveness analysis

2005 NHS Economic Evaluation Database.